Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with Ulcerative Colitis (UC) who have given written consent to take part in the study
- People who are 18 years of age or older at the time they started treatment with ozanimod or azathioprine, or at the time consent was given (whichever came first)
- People whose starting dose of oral steroids was at least 30 mg per day (measured in prednisolone or an equivalent steroid)
- People who started taking ozanimod or azathioprine after they had already begun taking oral steroids, with both medications being taken at the same time (people who started steroids and ozanimod or azathioprine on the exact same day are not included)
- For the ozanimod group: people who still had noticeable UC symptoms, such as rectal bleeding or significant overall symptom scores, at the time they started ozanimod
- For the azathioprine group: people who began azathioprine treatment after February 2019
Who may not be able to join:
- People whose UC symptoms did not improve, or got worse, after taking oral steroids at a dose of at least 30 mg per day for two weeks (based on a standard symptom scoring tool called PRO2)
- People who have other health conditions that require them to keep taking steroids on an ongoing basis (steroid inhalers or creams applied to the skin are not included in this rule)
- People who took part in another clinical study that involved a treatment intervention during the time period this study is looking at
- People whom the doctor running the trial considers unsuitable for enrollment for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants achieving steroid-free symptomatic remission
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.